The agreement sees San Diego-based Janux in line for around $500 million in milestones apiece for two T-cell engager therapies ... VelosBio and its anti-ROR1 antibody-drug conjugate (ADC ...

This advancement builds upon the achievements of monoclonal antibodies, which were first introduced in the 1970s and transformed targeted therapies by providing specific binding to individual epitopes ...

The novel CAPTN-3 technology utilizes a tri-specific antibody approach to activate both T cells and NK cells, targeting the 5T4 antigen found in various solid tumors associated with poor clinical ...

04, 2024 (GLOBE NEWSWIRE) -- Purple CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager ...

NEW YORK – The European Commission on Wednesday approved Amgen's bi-specific T-cell engager Blincyto (blinatumomab) as part of consolidation therapy for the treatment of adult patients with newly ...

(Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for ... to advance CRG-023, its tri-specific CAR T, into a Phase 1 dose ...

The company will continue the development of its CRG-023 tri-specific CAR T therapy, targeting multiple B-cell malignancies, and plans to initiate a Phase 1 dose escalation study in the second ...

Brian Feth, Jonathan Grinstein, PhD, Beth Willers, and Laks Pernenkil go behind the headlines to discuss major news announcements made during the JP Morgan Healthcare Conference, a wave of new ...